Anthem opens an insurance pathway for Alzheimer’s blood testing
Coverage for C2N’s PrecivityAD2 test turns blood-based Alzheimer’s evaluation into a reimbursement milestone rather than only a scientific one.
Diagnostics often struggle commercially even after strong clinical evidence because patients still need a viable payment pathway.
What happened
C2N Diagnostics announced that eligible Anthem Blue Cross and Blue Shield members will receive coverage under a medical policy for the PrecivityAD2 blood test beginning October 1, 2026.
The test helps clinicians evaluate adults with cognitive decline by estimating the likelihood of amyloid pathology using blood biomarkers.
It remains a clinician-ordered diagnostic aid rather than a standalone diagnosis.
Why it matters
The milestone is reimbursement.
Blood-based testing could offer a less-invasive route to Alzheimer’s evaluation, but adoption depends on whether clinicians can order it without creating prohibitive costs for patients.
Coverage from a major insurer could accelerate real-world use and place pressure on the broader diagnostic ecosystem to adapt.
The bigger picture
Healthcare innovation increasingly depends on payment infrastructure as much as technical performance.
The products that scale are often those that secure a place inside reimbursement pathways. C2N’s coverage milestone is a strong example.